SHANGHAI SHENQI PHARMACEUTICAL INVESTMENT MANAGEMENT CO., LTD. Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Share Price Shanghai S.E.
Equities
900904
CNE0000003X8
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.417 USD | +0.97% |
|
+0.24% | -36.34% |
| Sales 2022 | 2.39B 329M 26.03B | Sales 2023 | 2.34B 322M 25.51B | Capitalization | 3.9B 537M 42.51B |
|---|---|---|---|---|---|
| Net income 2022 | 48M 6.61M 523M | Net income 2023 | 57M 7.84M 621M | EV / Sales 2022 | 1.61 x |
| Net cash position 2022 | 371M 51.04M 4.04B | Net cash position 2023 | 483M 66.48M 5.26B | EV / Sales 2023 | 1.46 x |
| P/E ratio 2022 |
91.4
x | P/E ratio 2023 |
69.2
x | Employees | 1,426 |
| Yield 2022 |
1.22% | Yield 2023 |
1.31% | Free-Float | 49.01% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.97% | ||
| 1 week | +0.24% | ||
| Current month | -27.73% | ||
| 1 month | -28.35% | ||
| 3 months | -36.14% | ||
| 6 months | -35.55% | ||
| Current year | -36.34% |
1 week
0.39
0.43
1 month
0.370.58
Current year
0.370.70
1 year
0.370.79
3 years
0.371.08
5 years
0.371.08
10 years
0.372.57
| Managers | Title | Age | Since |
|---|---|---|---|
Bin Feng
CEO | Chief Executive Officer | 52 | 30/06/05 |
Ke Jing Wu
SEC | Corporate Secretary | 47 | 27/04/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shi Gui Chen
BRD | Director/Board Member | 61 | 28/06/20 |
Bin Feng
CEO | Chief Executive Officer | 52 | 30/06/05 |
Zhi Ting Zhang
BRD | Director/Board Member | 80 | 25/06/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/06/24 | 0.417 | +0.97% | 37,600 |
| 27/06/24 | 0.413 | -1.43% | 58,100 |
| 26/06/24 | 0.419 | +3.97% | 243,300 |
| 25/06/24 | 0.403 | +1.26% | 28,500 |
| 24/06/24 | 0.398 | -4.33% | 122,100 |
End-of-day quote Shanghai S.E., June 27, 2024
More quotes
Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. is a China-based company principally engaged in research and development, manufacture and sale of pharmaceuticals. The Companyâs products are targeted for the treatment of influenza, cardio cerebrovascular diseases, rheumatoid bone diseases and in the areas of oncology, antifungal, antipyretic and gynaecology. The Company's main products include cantharidin sodium vitamin B6 injection, cantharidin sodium injection and other Chinese patent drug products. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
01/09/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 815B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +2.04% | 224B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- 600613 Stock
- 900904 Stock
